Related Experiment Video

Updated: Jul 5, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

325

Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Te-An Lee1,2, En-Yun Tsai1,3, Shou-Hou Liu1

  • 1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

Cancer Research
|January 17, 2024
PubMed

Insights

Targeting post-translational modifications (PTM) of Programmed Death-1 (PD-1) in T cells can overcome immune suppression in cancer. This approach enhances antitumor immunity and improves responses to anti-PD-1 therapies.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Effector T cell activation upregulates Programmed Death-1 (PD-1), which inhibits T cell activity via its ligand PD-L1.
  • Post-translational modifications (PTMs) like glycosylation, phosphorylation, ubiquitination, and palmitoylation critically regulate PD-1 protein stability, localization, and interactions.

Purpose of the Study:

  • To explore targeting PD-1 PTMs as a therapeutic strategy to enhance antitumor immunity.
  • To investigate methods for modulating PD-1 PTMs to overcome PD-1-mediated immunosuppression in cancer.

Main Methods:

  • Investigating small-molecule inhibitors to suppress signaling pathways inducing PD-1 PTMs.
  • Utilizing monoclonal antibodies (mAbs) to directly target PD-1 PTMs on T cells.

Main Results:

  • Preliminary studies indicate that targeting PD-1 PTMs is a promising therapeutic strategy.
  • Modulating PD-1 PTMs shows potential to enhance the efficacy of anti-PD-1 therapies.

Conclusions:

  • Targeting PD-1 PTMs represents a novel approach to potentiate anti-PD-1 cancer immunotherapy.
  • Further research into PD-1 PTMs could lead to improved treatments for enhancing antitumor responses.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K